Our results suggest that the EGFR mutation status assessed prior to chemotherapy may not accurately reflect the mutation status post-chemotherapy, which supports a “real-time” tumor profiling in the personalized therapy of NSCLC. The gene discussed is EGFR; the disease is neoplasm.